CytomX Therapeutics CEO Sean McCarthy's 2022 pay falls 31% to $3M
CytomX Therapeutics reports 2022 executive compensation
By ExecPay News
Published: April 27, 2023
CytomX Therapeutics reported fiscal year 2022 executive compensation information on April 27, 2023.
In 2022, five executives at CytomX Therapeutics received on average a compensation package of $1.7M, a 20% decrease compared to previous year.
Average pay of disclosed executives at CytomX Therapeutics
Sean A. McCarthy, Chief Executive Officer, received $3M in total, which decreased by 31% compared to 2021. 52% of McCarthy's compensation, or $1.6M, was in option awards. McCarthy also received $398K in non-equity incentive plan, $623K in salary, $429K in stock awards, as well as $5K in other compensation.
Amy Peterson, Chief Operating Officer, received a compensation package of $1.8M, which decreased by 18% compared to previous year. 40% of the compensation package, or $747K, was in other compensation.
Carlos Campoy, Chief Financial Officer, earned $1.4M in 2022, a 2% increase compared to previous year.
Lloyd A. Rowland, Senior Vice President,, received $1.2M in 2022, which decreases by 15% compared to 2021.
Jeff Landau, Senior Vice President and Chief Business Officer, earned $1.1M in 2022, a 40% decrease compared to previous year.
Related executives
Sean McCarthy
CytomX Therapeutics
Chief Executive Officer
Lloyd Rowland
CytomX Therapeutics
Senior Vice President,
Jeff Landau
CytomX Therapeutics
Senior Vice President and Chief Business Officer
Amy Peterson
CytomX Therapeutics
Chief Operating Officer
Carlos Campoy
CytomX Therapeutics
Chief Financial Officer
You may also like
Source: SEC filing on April 27, 2023.